# A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct05067140/  
OnCo record `nct05067140` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05067140 by Novartis Pharmaceuticals, with 164 participants enrolled, started 2021-09-02 and due to reach its primary completion in 2027-05-25. Interventions recorded: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT). Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05067140
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 164

## Sources

- ClinicalTrials.gov NCT05067140: https://clinicaltrials.gov/study/NCT05067140

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct05067140.json